The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski
DAVOS, Switzerland, May 26 (Reuters) – Although cancer screening and diagnosis was hit by the coronavirus pandemic, resulting advances in medical technology and greater diversity in clinical trials could help treatments in the future, an AstraZeneca executive said.
Testing and diagnosis rates for cancer dropped by 15% to 25% over the past two years as people skipped routine checkups, Dave Fredrickson, executive vice president of oncology at AstraZeneca, told the Reuters Global Markets Forum in Davos.
"What that means is that we are diagnosing cancer patients late," Fredrickson said this week, with cancer outcomes being best when diagnosed early.
Efforts to minimise patients having to go to healthcare facilities, wider adoption of telemedicine, and bringing trials to patients rather than have patients come to trials are "particularly important," Fredrickson said.
"Clinical trial diversity is one of the most important steps to … deliver cancer therapies in an equitable way across the globe," he said.
Fredrickson said he was more optimistic on the detection and treatment of lung and breast cancer, as new drugs and treatment plans have improved survival rates in certain settings.
Public-private partnerships will be important in improving cancer diagnosis and survival rates, he said, pointing to Egypt's strategy to tackle prevalent cancers and U.S. President Joe Biden's revival of the "Cancer Moonshot" initiative.
The programme, an Obama administration initiative revived by Biden in February, aims to improve cancer detection and prevention, while encouraging cancer research. read more
(This interview was conducted in the Reuters Global Markets Forum. Join GMF on Refinitiv Messenger: https://refini.tv/33uoFoQ)
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved
